Yahoo Finance report covering Cencora Inc. (COR) market action, institutional positioning, and fundamental catalysts.
Why COR Stock advanced +0.09% Today — RQD Quant Desk Flash
Cencora Inc. (COR) earns a Roarable Rating of B- (Buy) with 70/100 RQD Confidence. High-quality cash engine (4% profit margin, 27% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is COR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Cencora Inc. (NYSE: COR) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 70/100 at a spot price of $330.84 (+0.09% 1D, market cap $63.07B). Pillar breakdown: Fundamental Cash Engine 19/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 14/20. Across 1016 tracked Health Care issuers, COR ranks #83 in composite RQD confidence.
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does COR compare to CAH and MCK in the Health Care sector?
▼
Within the Health Care sector (Other Pharmaceuticals), COR carries a Roarable B- (70/100 RQD), trailing P/E of 40.6x, gross margin of 3.6%, and ROIC of 26.8%. By comparison, CAH (Cardinal Health Inc.) holds a B grade (73/100 RQD, P/E 37.2x, ROIC 29.7%, cap $58.14B) and MCK (McKesson Corporation) posts a A- grade (85/100 RQD, P/E 24.0x, ROIC 38.6%, cap $114.36B). Among the 5-stock peer group, HLF leads on earnings multiple (5.9x) while MCK leads on capital efficiency (38.6% ROIC).
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for COR?
▼
Per COR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001140859), Cencora Inc. generated $321.33B in revenue (+9.3% YoY), $1.55B in net income, and $3.21B in free cash flow against $78.36B in total assets and $7.58B in total debt. Key quantitative strengths: Strong cash generator (4% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Priced at 41x earnings—high expectations leave less room for a lukewarm quarter.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
SEC XBRL FY 2025 (10-K): 1% FCF Margin ($3.21B FCF) & 3.6% Gross Margin
SEC Form 4 / 13F Thermometer: 70% Net Buy • Cannibal Buyback (-1.80% YoY Shares)
Macro rate sensitivity & RSI-14 (53.8) create a -9 pt regime headwind
⚔️ Adversarial Opposing Case: Why the COR Bull Thesis Could Fail
Even with a 70/100 (B-) score, COR faces multiple-compression risk if 40.6x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Priced at 41x earnings—high expectations leave less room for a lukewarm quarter.
Dilution & Margin Drag: Cannibal Buyback (-1.80% YoY Shares) — any gross margin slip below 15.0% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($323.76) or 200D SMA ($316.84) invalidates the momentum regime and cuts Target Base ($348.71) toward Bear Floor ($271.29).
Why COR Stock advanced +0.09% Today — RQD Quant Desk Flash
Cencora Inc. (COR) advanced +0.09% to $330.84, trading at 65% of its 52-week range ($244.82 – $377.54). High-quality cash engine (4% profit margin, 27% return on capital) with steady institutional support.
- ▸Technical Tape: Trading at 65% of its 52-week range ($244.82 – $377.54) with RSI-14 at 53.8 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±4.2% around $330.84 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable B- (Buy) backed by 3.6% gross margin and $3.2B annual free cash flow.
Seeking Alpha report covering Cencora Inc. (COR) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Cencora Inc. (COR) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Cencora Inc. (COR) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Cencora Inc. (COR) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Cencora Inc. (COR) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Cencora Inc. (COR) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Cencora Inc. (COR) market action, institutional positioning, and fundamental catalysts.
AbbVie boasts faster revenue growth and stronger cash generation, while Bristol Myers trades at half the valuation multiple, a classic growth-versus-value showdown.
Cencora (COR) has moved into the spotlight after agreeing to buy American Oncology Network in a deal valued at up to US$2.4b. The transaction reshapes its community cancer care footprint. Cencora’s latest move comes afte
Scheduled RQD Strong Buys & Whale Accumulation Briefing (COR Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
COR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +9.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on COR today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for COR. Explore sector supply chains on /butterfly.
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (COR)
1. Head-to-Head Health Care Peer Comparison (COR vs. CAH, MCK, HLF, NUS)
Industry: Other Pharmaceuticals (10 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Cencora Inc. (COR) ranks #83 by composite RQD confidence (70/100, grade B-) and #31 by equity capitalization ($63.07B). Within this direct 5-issuer industry benchmark cohort, HLF leads on earnings valuation at 5.9x trailing P/E, while MCK leads on capital efficiency and profitability with 38.6% ROIC and 3.6% gross margin. MCK currently holds the highest overall quantitative score in the immediate peer group at 85/100 (A-) compared with COR at 70/100 (B-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| COR
ACTIVE
Cencora Inc. | B- | 70/100 | 40.6x | 3.6% | 26.8% | +0.09% | $63.07B | Benchmark Subject |
| CAH Cardinal Health Inc. | B | 73/100 | 37.2x | 3.7% | 29.7% | -0.24% | $58.14B | /cah-vs-cor → |
| MCK McKesson Corporation | A- | 85/100 | 24.0x | 3.6% | 38.6% | +1.40% | $114.36B | /mck-vs-cor → |
| HLF Herbalife Ltd. | C | 64/100 | 5.9x | 77.9% | 34.4% | +0.93% | $1.36B | /hlf-vs-cor → |
| NUS Nu Skin Enterprises Inc. | D+ | 53/100 | — | 69.4% | 6.7% | -0.85% | $228.3M | /nus-vs-cor → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-09-30 • CIK 0001140859In its most recent audited fiscal period (FY2025, filed 2025-09-30), Cencora Inc. (COR) reported GAAP revenue of $321.33B (+9.3% vs. FY2024 revenue of $293.96B , and +22.6% cumulative change since FY2023) , GAAP net income of $1.55B, operating cash flow of $3.88B, and free cash flow of $3.21B (+7.0% YoY). On the balance sheet, COR closed FY2025 with $78.36B in total assets against $7.58B in total debt (Altman Z-Score: 5.27, Piotroski F-Score: 6/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-09-30 | $321.33B | $1.55B | $3.88B | $3.21B | $78.36B | $7.58B |
| FY2024 (FY) | 2024-09-30 | $293.96B | $1.51B | $3.48B | $3.00B | $69.05B | $5.94B |
| FY2023 (FY) | 2023-09-30 | $262.17B | $1.75B | $3.91B | -$7.89B | $314.61B | $73.62B |
3. COR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs COR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Cencora Inc. (NYSE: COR) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 70/100 at a spot price of $330.84 (+0.09% 1D, market cap $63.07B). Pillar breakdown: Fundamental Cash Engine 19/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 14/20. Across 1016 tracked Health Care issuers, COR ranks #83 in composite RQD confidence.
How does COR compare to CAH and MCK in the Health Care sector?
Within the Health Care sector (Other Pharmaceuticals), COR carries a Roarable B- (70/100 RQD), trailing P/E of 40.6x, gross margin of 3.6%, and ROIC of 26.8%. By comparison, CAH (Cardinal Health Inc.) holds a B grade (73/100 RQD, P/E 37.2x, ROIC 29.7%, cap $58.14B) and MCK (McKesson Corporation) posts a A- grade (85/100 RQD, P/E 24.0x, ROIC 38.6%, cap $114.36B). Among the 5-stock peer group, HLF leads on earnings multiple (5.9x) while MCK leads on capital efficiency (38.6% ROIC).
What are the biggest fundamental strengths and SEC risk factors for COR?
Per COR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001140859), Cencora Inc. generated $321.33B in revenue (+9.3% YoY), $1.55B in net income, and $3.21B in free cash flow against $78.36B in total assets and $7.58B in total debt. Key quantitative strengths: Strong cash generator (4% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Priced at 41x earnings—high expectations leave less room for a lukewarm quarter.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is COR trading relative to its 50-day, 200-day, and 52-week technical levels?
COR last traded at $330.84 (+0.09% on volume of 1,347,723 shares), positioning the stock +2.19% above its 50-day simple moving average ($323.76) and +4.42% above its 200-day simple moving average ($316.84). Across its 52-week range of $244.82 to $377.54, COR sits at the 64.8% percentile with a 14-day RSI of 53.8 (NEUTRAL RANGE) and an implied next-earnings move of ±4.2% ($316.94 to $344.74).
COR Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is COR stock moving today?
Why COR Stock advanced +0.09% Today — RQD Quant Desk Flash. High-quality cash engine (4% profit margin, 27% return on capital) with steady institutional support.
COR — Cencora Inc.: What the Facts Mean to a Prospective Investor
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, COR scores 70 out of 100, a letter grade of B-, with the verdict label "Roarable Buy — Sound Institutional Accumulation." The fundamental cash engine pillar scores 19 of 20, citing ROIC of 26.8% and FCF yield of 5.08%, making it the strongest pillar and the main upside driver in the rating. Whale 13F flow scores 13 of 20 for institutional accumulation and options positioning, suggesting institutional interest is present but not dominant. Insider conviction scores 14 of 20 based on SEC Form 4 and Congressional PTR cluster flow. Macro regime fit scores 11 of 20, reflecting a beta of 0.88 and sector sensitivity, the weakest pillar and a signal that the stock's market-relative behavior is only moderately favorable. Forensic balance sheet scores 13 of 20, citing Altman Z of 5.27, Piotroski F of 6/9, and Debt/Equity of 3.97; the Z-score is strong while the leverage ratio warrants attention. For a prospective investor, the key tradeoff is a high-quality cash-return profile against a valuation that the market data shows at 40.6x trailing earnings and 21.6x EV/EBITDA, alongside thin reported margins. This is analytical context, not personalized financial advice.
Snapshot
Business
Cencora Inc. is a NYSE-listed issuer in the Health Care sector and Other Pharmaceuticals industry, per the SEC profile. Beyond its sector and industry classification, the source data does not describe its specific products, customers, or revenue model. The reported revenue of $321332.8M for FY 2025 indicates a very large operating scale, but the source data does not explain how that revenue is generated.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $321332.8M | $2628.6M | $1554.2M | N/A | $3207.1M | $1753.1M | $7579.5M |
| FY 2024 | $293958.6M | $2175.2M | $1509.1M | N/A | $2997.5M | $3224.3M | $5935.3M |
| FY 2023 | $262173.4M | $2340.7M | $1745.3M | N/A | $-7886.5M | N/A | $73618.3M |
Per the SEC financials, revenue grew from $262173.4M in FY 2023 to $321332.8M in FY 2025, while net income moved from $1745.3M to $1554.2M over the same span. Market data shows gross margin of 3.6%, operating margin of 0.8%, and net margin of 0.5%, and ROIC of 26.8%. The forensic section reports an Altman Z-Score of 5.27 and a Piotroski F-Score of 6/9. Debt/Equity of 3.97 and reported debt rising to $7579.5M in FY 2025 from $5935.3M in FY 2024 point to a leveraged balance sheet, while the FY 2023 debt figure of $73618.3M appears in the source without further explanation.
Recent Catalysts & News Wire Analysis
The news wire contains six items, all tagged to COR with a YELLOW light and MARKET WIRE impact label, from Yahoo Finance, Seeking Alpha, Benzinga, TradingView, and Simply Wall St. Headlines include "Cencora (COR): 3 Reasons We Love This Stock," "AI Disruption May Benefit Cencora More Than Hims & Hers (NYSE:COR)," "Cencora (COR) Stock Still Looks Undervalued After Its 173% Run," "Cencora Gears Up to Report Q4 Results: How to Play the Stock?," and "Cencora (COR) Has Investors Asking A Bigger Question." The summaries are generic market-action descriptions and do not state specific catalyst details. Potential watch items implied by headlines include an upcoming Q4 results report and a reference to a prior 173% run, though the source does not quantify either. The Butterfly Supply-Chain Graph reports no supply-chain relationships and no proprietary signals.
Open Questions
- What drove the revenue expansion and how durable is the reported gross margin of 3.6% given the margin profile?
- What explains the FY 2023 free cash flow deficit of $-7886.5M and the $73618.3M debt figure, and how did the balance sheet move to its current position?
- Why is EPS unreported for all three periods, and how does the 8.14 TTM EPS reconcile with reported net income?
- What specific catalysts are expected around the upcoming Q4 results, and what do they imply for the 37.8x forward multiple?
- What institutional holdings and insider transactions support the whale and insider pillar scores, given the holders section is empty?
COR Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Cencora Inc. (COR) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Cencora Inc. (COR) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Cencora Inc. (COR) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Cencora Inc. (COR) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Cencora Inc. (COR) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Cencora Inc. (COR) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Cencora Inc. (COR) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Cencora Inc. (COR) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Cencora Inc. (COR) market action, institutional positioning, and fundamental catalysts.
COR Bull vs. Bear Conversation Board — What's Your Call at $330.84?
🔥 Official Bull vs. Bear Debate: Is COR (B- • RQD 70/100) a Buy at $330.53?
Welcome to the COR (Cencora Inc.) Roar Pit. Current RQD Composite is 70/100 (Roarable Buy — Sound Institutional Accumulation) in Other Pharmaceuticals. Bulls point to capital efficiency (26.8% ROIC), while bears focus on valuation multiple compression (40.6x trailing P/E). Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Pump the brakes on COR — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on COR, but look at what you are paying: 40.6x trailing P/E with 3.6% gross margins. Unless Cencora Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
COR cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on COR, the market is fixating on short-term headline noise in Other Pharmaceuticals and ignoring the balance sheet and cash flow trajectory. At $330.53 (52-wk range $244.82 - $377.54), any beat on forward guidance forces shorts and underweight funds to chase.